Clinical Edge Journal Scan

Reproductive tract infections associated with lower risk and better prognosis in breast cancer


 

Key clinical point: Presence of reproductive tract infections had a protective effect against the development of breast cancer (BC) and was associated with a better prognosis in patients with BC.

Major finding: Reproductive tract infections were associated with a lower risk for BC (odds ratio [OR] 0.80; 95% CI 0.65-0.98). Patients with reproductive vs non-reproductive tract infections showed improved overall survival (hazard ratio [HR] 0.61; 95% CI 0.40-0.94), whereas the risk for disease progression was lower in women with reproductive tract infections and >327 vs ≤327 menstrual cycles (HR 0.52; 95% CI 0.34-0.79).

Study details: Findings are from a case-control study including 1003 patients with BC and 1107 cancer-free control individuals and a cohort study including 4264 patients with BC, of which 685 women had a history of reproductive tract infections.

Disclosures: This study was funded by the National Natural Science Foundation of China and Science and Technology Planning Project of Guangdong Province. The authors declared no conflicts of interest.

Source: Li Y et al. Interaction of reproductive tract infections with estrogen exposure on breast cancer risk and prognosis. BMC Womens Health. 2023;23:238 (May 8). Doi: 10.1186/s12905-023-02383-3

Recommended Reading

Genomic assay changes minds on HER2+ BC treatment
MDedge Hematology and Oncology
HR+ early BC patients could briefly interrupt endocrine therapy to attempt pregnancy
MDedge Hematology and Oncology
Anthracycline+taxane combo reduces BC recurrence more effectively than either drug alone
MDedge Hematology and Oncology
Better lifestyle index scores associated with improved mortality and disease recurrence in high-risk BC
MDedge Hematology and Oncology
Postmastectomy implants did not increase risk for squamous cell carcinoma in BC patients
MDedge Hematology and Oncology
HER2+ early BC: Extent of disease at diagnosis may predict risk for relapse even after pCR
MDedge Hematology and Oncology
125I seed placement before neoadjuvant chemotherapy good marking method for metastatic lymph nodes in BC
MDedge Hematology and Oncology
Anlotinib-chemotherapy combo shows good efficacy and safety in metastatic TNBC
MDedge Hematology and Oncology
Are family members of early-onset BC patients at risk for discordant early-onset cancers?
MDedge Hematology and Oncology
Breast cancer survivors face increased risk for sexual dysfunction
MDedge Hematology and Oncology